PRMT1 and breast carcinoma: Accumulating evidence suggests that PRMT1 is aberrantly overexpressed in multiple cancers, driving proliferation, invasion, metastasis, and chemoresistance.[12, 13, 15] For example, PRMT1 is elevated in breast cancer tissues, and its inhibition suppresses tumor growth.[16] Similarly, in esophageal squamous cell carcinoma (ESCC), PRMT1 overexpression correlates with poor prognosis and enhances stem‐like properties, chemoresistance, and tumorigenicity.[12b] However, its precise role in HNSCC remains unclear.